Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
